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Abstract: The purpose of this study is to research the expression of DNA methylation-related proteins in phyllodes 
tumors of the breast and to study the implication on patient outcomes. We generated tissue microarrays (TMAs) 
of 196 phyllodes tumors (PT) and performed immunohistochemical staining for 5-meC and the DNA methylation-
related proteins DNMT1 and ISL-1. The staining results were analyzed and compared with clinicopathologic param-
eters. A total of 196 cases were included in this study, of which 153 were benign, 27 were borderline, and 16 were 
malignant. The levels of DNMT1, 5 meC, and ISL-1 in the stromal component of tumors increased with increasing 
grade (P<0.001). Especially, high stromal positivity of DNMT1 and ISL-1 were associated with increased distant 
metastasis (P=0.001, and P=0.013, respectively). Univariate analysis for factors associated with decreased disease 
free survival and overall survival identified DNMT1 high positivity (P=0.002 and P<0.001, respectively) and stromal 
ISL-1 high positivity (P<0.001 and P<0.001, respectively). Among borderline phyllodes tumors, stromal DNMT1 high 
positivity was associated with decreased OS (P=0.015). In conclusion, DNA methylation and expression of methyl-
ation-related proteins in the stromal component increased with increasing histologic grade in phyllodes tumors. In 
addition, overexpression stromal expression of DNMT1 and ISL-1 was associated with poor prognosis.
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Introduction
Phyllodes tumors are a relatively rare tumor 
type, accounting for 0.3-1.5% all breast tumors, 
and have histological features similar to fibro-
adenoma, a fibroepithelial tumor. Establishing 
an accurate differential diagnosis including 
phyllodes tumors is difficult due to their hetero-
geneous histological appearance [1, 2]. 
Clinically, phyllodes tumors are known to be 
malignant and recurrent and can metastasize 
to a number of different sites [3]. Although 
there are differing opinions among researchers 
regarding histologic classification of phyllodes 
tumors, the WHO classifies the histologic types 
of phyllodes tumor as benign, borderline, and 
malignant [2]. According to this classification 
scheme, the frequency of phyllodes tumor 
recurrence and distance metastasis increase 
with increasing histologic grade and are thus 
reflective of aggressiveness.
Insensitivity to growth inhibitory signals is an 
important difference between normal cells and 
cancer cells and is meditated primarily by tumor 
suppressor genes [4]. DNA hypermethylation is 
an important mechanism of inhibition of tumor 
suppressor genes and is catalyzed by DNA 
methyltransferases (DNMTs) [5]. DNMT1, 
DNMT2, DNMT3A, and DNMT3B have all been 
identified as DNA methyltransferase genes. 
Among these genes, DNMT1 is both the most 
common and most important gene involved in 
maintenance of methyltransferase activity in 
humans. The DNA residue 5-methylcytosine 
(5-MeC) is generated by DNMT1 via the addi-
tion of a methyl group to the 5’ position of the 
cytosine ring in CpG dinucleotides and is a 
marker of DNMT1 activity. In addition, a previ-
ous breast cancer study reported that insulin 
gene enhancer binding protein-1 (ISL-1) is a 
direct target of DNMT1 [6].
A number of previous studies have studied the 
methylation status of genes in phyllodes tumors 
[7-9], where DNA promoter methylation appears 
to be more frequent compared to follicular ade-
nomas [8]. In addition, one study reported that 
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the frequency of methylation in phyllodes 
tumors increases with increasing grade [9]. 
Given these data, we hypothesized that the 
expression of DNA methylation-related proteins 
will increase in phyllodes tumors. Thus, the pur-
pose of this study was to investigate the expres-
sion and implications of DNA methylation-relat-
ed proteins in phyllodes tumor of the breast.
Materials and methods
Patient selection
We obtained tissue samples from patients who 
were diagnosed with phyllodes tumor and who 
underwent surgery (from 2000 to 2010) in the 
Department of Pathology in Severance Hos- 
pital. The study was approved by the Institutional 
Review Board of Yonsei University Severance 
Hospital. All tissues were fixed in 10% buffered 
formalin and embedded in paraffin. All archival 
hematoxylin and eosin (H&E)-stained slides for 
each case were reviewed by two pathologists 
(JS Koo and W Jung). The histologic grade of 
phyllodes tumors was evaluated using H&E-
stained slides according to the WHO blue book 
criteria [2]. We also obtained associated clini-
cal characteristics such as patient age, tumor 
recurrence, distant metastasis, and survival.
Tissue microarray
A representative area of each H&E-stained 
tumor slide was selected, and the correspond-
ing location on the surface of the paraffin block 
was marked. The selected area was then 
punched out, and a 5 mm tissue core was 
placed in a 5×6 recipient block using a biopsy 
needle. Two tissue cores were obtained to mini-
mize extraction bias. Each separate tissue core 
was given a unique tissue microarray location 
number that was linked to a database contain-
ing the associated clinical pathology data.
Immunohistochemistry 
The antibodies used for immunohistochemistry 
in this study are shown in Table 1. All immunos-
immunoglobulin and visualized with peroxi-
dase-labeled streptavidin using a labeled strep-
tavidin biotin kit with 3,3’-diaminobenzidine 
chromogen as the substrate. As a negative con-
trol, the primary antibody incubation step was 
omitted. Slides were counterstained with Harris 
hematoxylin. All immunohistochemical markers 
were analyzed by light microscopy. 
Immunohistochemical staining data were eval-
uated by multiplying the scores assigned for 
proportion of stained cells and immunostaining 
intensity. Specifically, the proportion of stained 
cells was scored as 0: negative, 1: less than 
30% of cells positive, and 2: more than 30% of 
cells positive. Likewise, immunostaining inten-
sity was scored as 0: negative, 1: weak, 2: mod-
erate, and 3: strong. A multiplied intensity and 
proportion score of 0-1 was deemed as a nega-
tive staining result, while a score of 2-6 was 
considered positive [10]. Stromal component 
positivity was divided into low positive (2-3) and 
high positive (4-6) categories.
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). 
Student’s t and Fisher’s exact tests were used 
to determine statistical significance for continu-
ous and categorical variables, respectively. The 
threshold for statistical significance was set as 
P<0.05. Kaplan-Meier survival curves and log-
rank statistics were used to evaluate time to 
tumor recurrence. Multivariate regression anal-
ysis was performed using Cox proportional haz-
ards model.
Results
Basal characteristics of phyllodes tumor
The basal characteristics of the 196 phyllodes 
tumor patients studied in this research are 
shown in Table 2. Among all cases, 153 were 
identified as benign, 27 were borderline, and 
Table 1. Source, clone, and dilution of the antibodies used 
Antibody Company Clone Dilution
DNA methylation-related proteins
    DNMT1 Abcam, Cambridge, UK 2B5 1:200
    5-meC Abcam, Cambridge, UK 33D3 1:200
    ISL-1 Abcam, Cambridge, UK Polyclonal 1:200
taining was performed using tissue 
sections that were formalin-fixed and 
paraffin-embedded. A microtome was 
used to obtained 5-μm-thick sections 
that were transferred to adhesive 
slides and dried at 62°C for 30 min-
utes. After incubation with primary 
antibodies, immunodetection was per-
formed with biotinylated anti-mouse 
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Table 2. Clincopathological characteristics of phyllodes tumor patients
Parameters Total N=196 (100%)
PT, Benign
N=153 (100%)
PT, Borderline
N=27 (100%)
PT, Malignant
N=16 (100%) P-value
Age (years, mean ± SD) 40.1±12.3 38.9±12.2 42.3±11.5 47.6±12.9 0.017
Tumor size (cm, mean ± SD) 4.0±2.6 6.7±4.6 4.3±2.5 3.6±2.1 <0.001
Stromal cellularity <0.001
    Mild 121 (61.7) 120 (78.4) 1 (3.7) 0 (0.0)
    Moderate 63 (32.1) 33 (21.6) 23 (85.2) 7 (43.8)
    Marked 12 (6.1) 0 (0.0) 3 (11.1) 9 (56.2)
Stromal atypia <0.001
    Mild 156 (79.6) 151 (98.7) 5 (18.5) 0 (0.0)
    Moderate 30 (15.3) 2 (1.3) 20 (74.1) 8 (50.0)
    Marked 10 (5.1) 0 (0.0) 2 (7.4) 8 (50.0)
Stromal mitosis <0.001
    0-4/10 HPFs 154 (78.6) 153 (100.0) 1 (3.7) 0 (0.0)
    5-9/10 HPFs 31 (15.8) 0 (0.0) 26 (96.3) 5 (31.2)
    ≥ 10/10 HPFs 11 (5.6) 0 (0.0) 0 (0.0) 11 (68.8)
Stromal overgrowth <0.001
    Absent 179 (91.3) 153 (100.0) 24 (88.9) 2 (12.5)
    Present 17 (8.7) 0 (0.0) 3 (11.1) 14 (87.5)
Tumor margin <0.001
    Circumscribed 176 (89.8) 150 (98.0) 20 (74.1) 6 (37.5)
    Infiltrative 20 (10.2) 3 (2.0) 7 (25.9) 10 (62.5)
Tumor recurrence 18 (9.2) 5 (3.3) 6 (22.2) 7 (43.8) <0.001
Distant metastasis 8 (4.1) 0 (0.0) 1 (3.7) 7 (43.8) <0.001
PT, phyllodes tumor; HPFs, high-power fields.
Table 3. DNA methylation and expression of proteins related to methylation according to phyllodes 
tumor grade
Parameters Total N=196 (100%)
PT, Benign
N=153 (100%)
PT, Borderline
N=27 (100%)
PT, Malignant
N=16 (100%) P-value
DNMT1 (E)* 0.473
    Negative 129 (72.1) 107 (70.4) 19 (82.6) 3 (75.0)
    Positive 50 (27.9) 45 (29.6) 4 (17.4) 1 (25.0)
DNMT1 (S) <0.001
    Low 183 (93.4) 151 (98.7) 23 (85.2) 9 (56.2)
    High 13 (6.6) 2 (1.3) 4 (14.8) 7 (43.8)
5 meC (E)* n/a
    Negative 179 (100.0) 152 (100.0) 23 (100.0) 4 (100.0)
    Positive 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
5 meC (S) <0.001
    Low 103 (52.6) 94 (61.4) 6 (22.2) 3 (18.8)
    High 93 (47.4) 59 (38.6) 21 (77.8) 13 (81.2)
ISL-1 (E)* 0.194
    Negative 149 (83.2) 128 (84.2) 19 (82.6) 2 (50.0)
    Positive 30 (16.8) 24 (15.8) 4 (17.4) 2 (50.0)
ISL-1 (S) <0.001
    Low 182 (92.6) 150 (98.0) 22 (81.5) 10 (62.5)
    High 14 (7.1) 3 (2.0) 5 (18.5) 6 (37.5)
*Seventeen tumors without an epithelial component were excluded. E, epithelial; S, stromal.
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16 were malignant. Age and tumor size 
increased with increasing histological grade 
(P=0.017 and P=0.001, respectively). Tumor 
recurrence and distance metastasis also 
increased with increasing histological grade 
(P<0.001). The eight examples of distance 
metastasis were all lung metastases.
Methylation and expression of methylation-
related proteins according to phyllodes tumor 
grade
In analyzing the methylation status and expres-
sion of methylation-related proteins according 
to histologic type of phyllodes tumor, the 
expression of methylation-related proteins in 
the epithelial component did not appear to be 
associated with histologic grade. On the other 
hand, DNMT1, 5 meC, and ISL-1 positivity in the 
stromal component exhibited significant differ-
ences according to histologic grade (Table 3 
and Figure 1). Specifically, as histologic grade 
increased, the ratios of DNMT1, 5 meC, and 
ISL-1 positivity increased (P<0.001). 
Correlations of methylation and the expression 
of methylation-related proteins with pathologic 
parameters
Comparison of methylation and expression of 
methylation-related proteins and pathologic 
parameters revealed that stromal DNMT1 high 
Figure 1. DNA methylation and expression of methylation-related proteins according to histologic grade of phyllodes 
tumor. Levels of DNMT1, 5 meC, and ISL-1 staining in the stromal component increased with increasing histologic 
grade.
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positivity was associated with distant metasta-
sis (P=0.001), stromal overgrowth (P<0.001), 
increased stromal atypia (P<0.001), and 
increased stromal mitosis (P<0.001). Likewise, 
high stromal 5 meC positivity was associated 
with increased stromal cellularity (P<0.001). 
Lastly, high stromal ISL-1 positivity was associ-
ated with distant metastasis (P=0.013), stro-
mal overgrowth (P<0.001), and infiltrative mar-
gin (P=0.001, Figure 2). 
Figure 2. Correlation of DNA methylation and expression of methylation-related proteins in phyllodes tumor accord-
ing to pathologic parameters.
Table 4. Univariate analysis of methylation and methylation-related proteins according to patient 
prognosis using the log-rank test
Parameters
No. of patients  
Total/recurrence/ 
metastasis
Disease-free survival Overall survival
Median survival
(95% CI) months P-value
Median survival
(95% CI) months P-value
DNMT1 (E)* 0.242 n/a
    Negative 129/6/1 174 (167-181) n/a
    Positive 50/5/0 134 (123-145) n/a
DNMT1 (S) 0.002 <0.001
    Low 183/14/4 169 (162-176) 179 (175-182)
    High 13/4/4 96 (65-127) 92 (58-125)
5meC (S) 0.067 n/a
    Low 103/6/0 172 (164-180) n/a
    High 93/12/8 155 (143-167) n/a
ISL-1 (E)* 0.633 n/a
  Negative 149/9/1 168 (162-175) n/a
    Positive 30/2/0 171 (155-186) n/a
ISL-1 (S) <0.001 <0.001
    Low 182/13/5 170 (163-176) 178 (173-182)
    High 14/5/3 82 (46-119) 106 (78-135)
*Seventeen tumors without an epithelial component were excluded. E, epithelial; S, stromal.
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Impact of methylation and expression of meth-
ylation-related proteins on patient prognosis
Univariate analysis to evaluate methylation sta-
tus and expression of methylation-related pro-
teins on phyllodes tumor patient prognosis 
showed that decreased DFS and OS were asso-
ciated with stromal DNMT1 high positivity 
(P=0.002 and P<0.001, respectively) and stro-
mal ISL-1 high positivity (P<0.001 and P<0.001, 
respectively, Table 4 and Figure 3). Univariate 
analysis of phyllodes tumor according to grade 
showed that high stromal DNMT1 positivity was 
associated with decreased OS (P=0.015) in 
borderline phyllodes tumors. According to mul-
tivariate Cox analysis, independent factors 
associated with decreased DFS consisted of 
histologic grade (hazard ratio: 7.087, 95% CI: 
1.857-27.05, P=0.004) and stromal overgrowth 
(hazard ratio: 10.78, 95% CI: 1.859-62.59, 
P=0.008), while stromal overgrowth was identi-
fied as an independent factor associated with 
decreased OS (hazard ratio: 59.47, 95% CI: 
3.258-1085, P=0.006, Table 5). 
Discussion
This research analyzed the relationships 
between patient outcomes and the methylation 
and expression of DNA methylation-related pro-
teins in phyllodes tumors of the breast. The 
results showed that 5 meC staining and the 
expression of DNMT1 and ISL-1 were increased 
in the stromal component of phyllodes tumors 
with increased histologic grade. Consistent 
with these results, previous studies have 
reported that TWIST1 [7-9] and RASSF1A [8, 9] 
are also significantly methylated in phyllodes 
tumors. Likewise, the methylation frequency of 
five genes (GSTP1, HIN-1, RAR-beta, RASSF1A, 
and Twist) has been showed to be increased in 
phyllodes tumors according to histologic grade 
[9]. The same study reported that, while the 
methylation profiles of benign and borderline/
malignant phyllodes tumors are distinguish-
able, those of borderline and malignant tumors 
are not [9]. In contrast to this result, we found 
that the expression of DNMT1 and ISL-1 was 
significantly higher in the stromal component of 
malignant phyllodes tumors compared to bor-
derline tumors. A possible explanation for this 
discrepancy is the use of different experimen-
tal methods. Specifically, while previous meth-
ylation studies targeting phyllodes tumor evalu-
ated the specific methylation status of genes of 
interest, we focused on the expression of pro-
teins involved in DNA methylation (DNMT1) and 
DNA-methylation target genes (ISL-1). Thus, the 
increased expression of DNA methylation-relat-
ed proteins according to histologic grade that 
was observed in this study may have been due 
Figure 3. Disease-free survival 
(A, B) and overall survival (C, D) 
according to DNA methylation 
status and expression of methyla-
tion-related proteins in phyllodes 
tumor. In borderline PTs, high 
stromal DNMT1 positivity was as-
sociated with decreased OS (E). 
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to carcinogenesis and/or tumor progression fol-
lowing epigenetic silencing of various tumor-
related genes by DNMT1, especially tumor sup-
pressor genes [4]. Thus, as histologic grade of 
phyllodes tumor increases, the number of 
genes that undergo methylation-induced silenc-
ing increases, which would be consistent with 
our observation that 5-MeC positivity and 
expression of DNMT1 were increased in higher 
grade tumors. 
In the present study, expression of DNMT1 and 
ISL-1 in the stromal component of phyllodes 
tumors was associated with increased distant 
metastasis. Consistent with this observation, 
previous studies have shown that DNMT1 
expression is associated with metastasis in 
both esophageal cancer [11] and stomach can-
cer [12], while ISL-1 expression is associated 
with metastasis in stomach cancer [13]. 
Increased metastasis following epigenetic 
silencing by DNA methylation of metastasis-
inhibiting genes has been reported [11, 14]. 
Such metastasis-related genes include proto-
cadherin 17, RASSF1A, and DAPK, which were 
mentioned previously. Among these, RASSF1A 
has been reported to undergo DNA methylation 
in phyllodes tumor [8, 9] and should be investi-
gated in similar future studies.
Our results showed that high levels of expres-
sion of DNMT1 and ISL-1 in the stromal com-
partment of phyllodes tumors were associated 
with poor prognosis. Consistently, high DNMT1 
expression is associated with poor prognosis in 
malignant lymphoma [15], renal cell carcinoma 
[16], pancreatic cancer [17], and bladder can-
cer [18], while high ISL-1 expression is associ-
ated with poor prognosis in gastric cancer [13]. 
Especially in borderline phyllodes tumors, high 
stromal DNMT1 expression was significantly 
associated with decreased OS.  Establishing an 
accurate clinical prognosis for borderline phyl-
lodes tumor is difficult because borderline 
high-grade tumors can be hard to distinguish 
from benign or malignant tumors [2]. An effec-
tive prognostic factor is therefore needed to 
overcome this problem. Importantly, our results 
suggest that stromal DNMT1 expression could 
serve as a prognostic marker of borderline phyl-
lodes tumors, a possibility that will require fur-
ther study.
A clinically significant outcome of this study is 
the identification of the epigenetic methylation-
related protein DNMT1 as a target in malignant 
phyllodes tumors. Specifically, by identifying an 
association between DNMT1 overexpression 
and increased tumor progression, our study 
supports the possibility of inhibiting tumorigen-
esis by re-expressing tumor suppressor genes 
that have been inhibited through selective 
DNMT1 inhibition [19]. Consistent with this 
possibility, numerous studies have already 
Table 5. Multivariate analysis of disease-free survival and overall-survival in phyllodes tumor patients 
Included factor
Disease-free survival Overall survival
Hazard 
ratio 95% CI P-value
Hazard 
ratio 95% CI P-value
Histologic grade 0.004 n/a
    Benign vs. borderline or malignant 7.087 1.857-27.05 n/a n/a
Stromal cellularity 0.317 0.475
    Mild vs. moderate or marked 0.336 0.040-2.847 2.805 0.165-47.59
Stromal atypia 0.671 0.866
    Mild vs. moderate or marked 0.671 0.106-4.246 0.812 0.072-9.118
Stromal mitosis 0.673 0.426
    0-4/10 HPFs vs. >4/10 HPFs 1.874 0.102-34.58 0.209 0.004-9.898
Stromal overgrowth 0.008 0.006
    Absent vs. Present 10.78 1.859-62.59 59.47 3.258-1085
Tumor margin 0.158 0.176
    Circumscribed vs. Infiltrative 0.395 0.109-1.436 0.333 0.068-1.638
DNMT1 (S) 0.191 0.687
    Low vs. High 0.374 0.086-1.631 0.701 0.125-3.934
ISL-1 (S) 0.075 0.432
    Low vs. High 2.901 0.899-9.369 1.976 0.362-10.78
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attempted to target DNMT1 in various types 
of cancer [19-22].
In conclusion, the expression of DNA methyla-
tion-related proteins in the stromal component 
of phyllodes tumors of the breast was found to 
increase with increasing histologic grade, and 
stromal DNMT1 and ISL-1 overexpression was 
associated with a poor prognosis. 
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